RFL

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

Retrieved on: 
Wednesday, March 13, 2024
Drug development, Patient, CYTH, Niemann–Pick disease, Research, Investment, RFL

NEWARK, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter of fiscal 2024 – and the six months ended January 31, 2024.

Key Points: 
  • NEWARK, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter of fiscal 2024 – and the six months ended January 31, 2024.
  • John will be an integral member of our team, as we advance our existing assets and evaluate additional opportunities for investment,” said Bill Conkling, CEO of Rafael Holdings.
  • During the second quarter of 2024, we increased our investment in Day Three Labs and now hold a majority interest in the company with 79% of the shares outstanding and began consolidating its financial results in the second quarter of 2024.
  • During the second quarter of 2024, we increased our investment in Day Three Labs and now hold a majority interest in the company with 79% of the shares outstanding and we began reporting consolidated its financial results in January 2024.

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Retrieved on: 
Thursday, December 14, 2023
Research, Investment, Patient, Laboratory, CYTH, RFL, Niemann–Pick disease

NEWARK, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter of fiscal 2024 - the three months ended October 31, 2023.

Key Points: 
  • NEWARK, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter of fiscal 2024 - the three months ended October 31, 2023.
  • “During fiscal 2024, we will continue to focus on advancing our existing portfolio and identifying strategic investments in companies which have the potential to generate value for our stockholders.
  • We believe our strong balance sheet affords us the opportunity to potentially capitalize on attractive investments,” said Bill Conkling, CEO of Rafael Holdings.
  • The year over year reduction in spending is due to the winding down of early-stage programs, including at Barer Institute.

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

Retrieved on: 
Monday, October 30, 2023
Research, NYSE, Laboratory, Niemann–Pick disease, CYTH, Dislocation, RFL, Patient, Pharmaceutical industry, Reinsurance, Airline, Inc.

NEWARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the fourth quarter and full year of fiscal 2023 - the three and twelve months ended July 31, 2023.

Key Points: 
  • NEWARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the fourth quarter and full year of fiscal 2023 - the three and twelve months ended July 31, 2023.
  • “During fiscal 2023, we made meaningful progress toward expanding our portfolio through strategic investments in companies which have the potential to generate value for our stockholders.
  • For the three months ended July 31, 2023, we incurred net income from continuing operations of $1.3 million, or $0.06 per share.
  • Research and development expenses were $1.3 million for the quarter compared to $1.8 million in the year ago period.

Retainers For Life Expands Operations to Canada Following Pilot Success

Retrieved on: 
Thursday, September 28, 2023
Wolk, RFL, Orthodontics, Retainer, CAO, Patient, SAN, Frustration, Pharmaceutical industry

SAN ANTONIO, Sept. 28, 2023 /PRNewswire/ -- Retainers For Life (RFL) announced today it will be expanding its operations in Canada, following record-breaking adoption during the company's Canadian pilot program.

Key Points: 
  • SAN ANTONIO, Sept. 28, 2023 /PRNewswire/ -- Retainers For Life (RFL) announced today it will be expanding its operations in Canada, following record-breaking adoption during the company's Canadian pilot program.
  • Retainers For Life, the orthodontic company modernizing retention, allows orthodontists to more easily capture lost revenue with their unique Smile Protection program.
  • With the program, practices can offer patients wholesale pricing on retainers, in exchange for a one-time membership fee.
  • "We had a feeling the Canadian market would be quick to adopt this program," shared Retainers For Life Chief Operations Officer Lorraine Porto.

Kigali International Financial Centre (KIFC) and Astana International Financial Centre (AIFC) sign a MoU, marking the beginning of a new financial partnership between Rwanda and Kazakhstan

Retrieved on: 
Wednesday, September 20, 2023
RFL, Astana International Financial Centre, Insurance, Sustainability, Partnership, Nursultan Nazarbayev International Airport, Investment, Corporate social responsibility, Research, Principles for Responsible Investment, CSR, Kigali International Airport, Publication, MOU, Biophysical environment, Memorandum of understanding, ESG, Responsibility, SRI, Management, Audit, Financial services, Security (finance), Fintech

ASTANA, Kazakhstan, Sept. 20, 2023 /PRNewswire/ -- Kigali International Financial Centre (KIFC), one of the newest and most promising financial centres in Africa, and Astana International Financial Centre (AIFC), one of the leading financial centres in Central Asia, have signed a Memorandum of Understanding (MOU) today.

Key Points: 
  • ASTANA, Kazakhstan, Sept. 20, 2023 /PRNewswire/ -- Kigali International Financial Centre (KIFC), one of the newest and most promising financial centres in Africa, and Astana International Financial Centre (AIFC), one of the leading financial centres in Central Asia, have signed a Memorandum of Understanding (MOU) today.
  • This marks the beginning of a new journey of partnership and cooperation for the two countries.
  • The partnership also aims to facilitate the sharing of information and expertise between the two entities to develop effective cooperation.
  • Nick Barigye, CEO of Rwanda Finance Limited (RFL) said:
    "This MoU is a milestone in the strengthening of Kigali International Financial Centre's relationship with other world-class Centres such as AIFC.

Kigali International Financial Centre (KIFC) and Astana International Financial Centre (AIFC) sign a MoU, marking the beginning of a new financial partnership between Rwanda and Kazakhstan

Retrieved on: 
Wednesday, September 20, 2023
RFL, Astana International Financial Centre, Insurance, Sustainability, Partnership, Nursultan Nazarbayev International Airport, Investment, Corporate social responsibility, Research, Principles for Responsible Investment, CSR, Kigali International Airport, Publication, MOU, Biophysical environment, Memorandum of understanding, ESG, Responsibility, SRI, Management, Audit, Financial services, Security (finance), Fintech

ASTANA, Kazakhstan, Sept. 20, 2023 /PRNewswire/ -- Kigali International Financial Centre (KIFC), one of the newest and most promising financial centres in Africa, and Astana International Financial Centre (AIFC), one of the leading financial centres in Central Asia, have signed a Memorandum of Understanding (MOU) today.

Key Points: 
  • ASTANA, Kazakhstan, Sept. 20, 2023 /PRNewswire/ -- Kigali International Financial Centre (KIFC), one of the newest and most promising financial centres in Africa, and Astana International Financial Centre (AIFC), one of the leading financial centres in Central Asia, have signed a Memorandum of Understanding (MOU) today.
  • This marks the beginning of a new journey of partnership and cooperation for the two countries.
  • The partnership also aims to facilitate the sharing of information and expertise between the two entities to develop effective cooperation.
  • Nick Barigye, CEO of Rwanda Finance Limited (RFL) said:
    "This MoU is a milestone in the strengthening of Kigali International Financial Centre's relationship with other world-class Centres such as AIFC.

CVS Health supporting customers, patients, members and colleagues as Hurricane Idalia approaches

Retrieved on: 
Tuesday, August 29, 2023
RFL, Medicaid, Pharmacy, Vaccination, Aetna, COVID-19, CVS, Health, Prescription, Medicine, CVS Pharmacy, Organization, Medicare, Sunlight, Humidity, Patient, Risk, Water, Weather, Commercial, CVS Health, Hand, NYSE, Safety, Pharmaceutical industry, Health insurance

WOONSOCKET, R.I., Aug. 29, 2023 /PRNewswire/ -- CVS Health® (NYSE: CVS) is actively preparing for Hurricane Idalia's impending landfall along Florida's Gulf Coast.

Key Points: 
  • WOONSOCKET, R.I., Aug. 29, 2023 /PRNewswire/ -- CVS Health® (NYSE: CVS) is actively preparing for Hurricane Idalia's impending landfall along Florida's Gulf Coast.
  • CVS Caremark®, the company's pharmacy benefit manager, is enabling pharmacy claims for one-time emergency refills of a 10-day supply of medication for plan members in impacted areas.
  • CVS Health is also contacting colleagues who are at risk from the storm to confirm they are safe and offer crisis support.
  • CVS Health remains dedicated to supporting its local communities and is in contact with disaster relief organizations to help communities respond to and recover from Hurricane Idalia.

Cyclo Therapeutics Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 15, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, RFL, Patent, European Patent Office, CYTH, Research, Sale, Science, Patient, NPC, Therapy, Conference, NYSE, Safety, Pharmaceutical industry

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the second quarter 2023.

Key Points: 
  • Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the second quarter 2023.
  • We remain focused on driving recruitment in our pivotal TransportNPC™ study of Trappsol® Cyclo™ and are on track to complete enrollment by the end of this year.
  • We are working diligently to bring a safe and effective treatment option where there remains a significant unmet need,” commented N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics.
  • Net loss for the quarter ended June 30, 2023 was approximately $4.6 million.

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

Retrieved on: 
Wednesday, August 2, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, RFL, Partnership, Act, CYTH, Hope, Regulation D, Sale, Niemann–Pick disease, Patient, NPC, Therapy, Cyclo, NYSE, Pharmaceutical industry

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has closed the previously announced private placement with Rafael Holdings, Inc. (NYSE:RFL) (“Rafael”) for the purchase of 4,000,000 shares of common stock of Cyclo Therapeutics and warrants to purchase an additional 4,000,000 shares of common stock of Cyclo Therapeutics, for an aggregate purchase price of $5,000,000.

Key Points: 
  • Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has closed the previously announced private placement with Rafael Holdings, Inc. (NYSE:RFL) (“Rafael”) for the purchase of 4,000,000 shares of common stock of Cyclo Therapeutics and warrants to purchase an additional 4,000,000 shares of common stock of Cyclo Therapeutics, for an aggregate purchase price of $5,000,000.
  • The warrants have an exercise price of $1.25 and a term of seven years.
  • Cyclo Therapeutics intends to use the net proceeds from the financing for working capital and general corporate purposes, including the support of its Trappsol® Cyclo™ development programs.
  • The securities have been issued by the Company directly to Rafael without the services of a placement agent or other intermediary.

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, June 13, 2023
RFL, Dislocation, Research, Therapy, Patient, NYSE, Pharmaceutical industry, Reinsurance, Inc.

NEWARK, N.J., June 13, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter of fiscal 2023 for the three months ended April 30, 2023, as well as the nine months ended April 30, 2023.

Key Points: 
  • NEWARK, N.J., June 13, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter of fiscal 2023 for the three months ended April 30, 2023, as well as the nine months ended April 30, 2023.
  • We believe that the current dislocation in the capital markets makes this a particularly opportune time,” said Bill Conkling, CEO of Rafael Holdings.
  • For the three months ended April 30, 2023, we incurred a net loss from continuing operations of $1.5 million, or $0.06 per share.
  • Research and development expenses were $0.7 million for the three months ended April 30, 2023.